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Abstract
Background: The relationship of elevated T cell activation to altered T cell differentiation profiles, each defining features of
HIV-1 infection, has not been extensively explored. We hypothesized that anti-retroviral suppression of T cell activation
levels would lead to alterations in the T cell differentiation of total and HIV-1 specific CD8+ T cell responses among recently
HIV-1 infected adults.
Methodology/Principal Findings: We performed a longitudinal study simultaneously measuring T cell activation and
maturation markers on both total and antigen-specific T cells in recently infected adults: prior to treatment; after the
initiation of HAART; and after treatment was halted. Prior to treatment, HIV-1 Gag–specific CD8+ T cells were predominantly
of a highly activated, intermediate memory (CD27+CD282) phenotype, while CMV pp65-specific CD8+ T cells showed a late
memory (CD272CD282), low activation phenotype. Participants with the highest fraction of late memory (CD272CD282)
HIV-1-specific CD8+ T cells had higher CD4+ T cell counts (rho=+0.74, p=0.004). In turn, those with the highest fraction of
intermediate memory (CD27+ CD282) HIV-1 specific CD8+ T cells had high total CD8+ T cell activation (rho=+0.68,
p=0.01), indicating poorer long-term clinical outcomes. The HIV-1 specific T cell differentiation profile was not readily
altered by suppression of T cell activation following HAART treatment.
Conclusions/Significance: A more differentiated, less activated HIV-1 specific CD8+ T cell response may be clinically
protective. Anti-retroviral treatment initiated two to four months after infection lowered T cell activation but had no effect
on the differentiation profile of the HIV-1-specific response. Intervention during the first month of acute infection may be
required to shift the differentiation phenotype of HIV-1 specific responses to a more clinically favorable profile.
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Introduction
Elevated CD8+ T cell activation is established early in HIV-1
infection [1], is a hallmark of HIV-1 disease [2] and predicts
subsequent poor clinical outcome in a manner independent of
viral load [1]. Furthermore, elevated CD8+ T cell activation, and
not viral load, distinguish pathogenic from non-pathogenic
lentiviral infections [3–6]. These observations have lead to a
general consensus that CD8+ T cell activation plays an important
role in the pathogenesis of immunodeficiency. Yet the mechanism
whereby elevated CD8+ T cell activation leads to immunodefi-
ciency during untreated HIV-1 disease remains unclear. The T
cell response to HIV-1 is marked by a second distinguishing
feature. Several groups have observed that HIV-1 specific CD8+
T cells fail to differentiate to a fully mature effector cell [7,8]. We
hypothesized that a block in T cell maturation may be related to
elevated activation on HIV-1 specific CD8+ T cells, and be
relieved by suppression of T cell activation levels by anti-retroviral
treatment (ART).
On encountering antigen CD8+ T cells differentiate from the
least differentiated (naı ¨ve or early memory) stage to the most
mature (memory/effector) stage. In this process, cell surface
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CD28, CD27, CD127) as CD8+ T cells differentiate and up-
regulated or re-expressed (CD57, CD45RA). While there is broad
general agreement on how to define a naı ¨ve T cell, there is not yet
a unified model that describes the process of human T cell
differentiation (reviewed by Appay et al 2008 [9]) but memory
cells can be divided into Early (EM), Intermediate (IM) and Late
(LM) stages using CD27 and CD28. T cell differentiation profiles
have been found to differ across antigen specificities, and may
relate to the effectiveness of long-term control [10,11]. The CMV-
specific CD8+ T cell response displays a predominantly late
memory phenotype. As CMV infection is typically well controlled
in adults, this suggests a more differentiated phenotype may be
beneficial [12]. The reverse is true for HIV-1-specific CD8+ T
cells, which are enriched for a more intermediate memory
phenotype. Likewise, in chronic, virulent HCV infection there is
an expansion of the intermediate memory and a lack of late
memory, HCV specific CD8+ cells [13]. Among EBV/HIV-1 co-
infected persons, the absence of differentiated EBV specific CD8+
T cells has been associated with EBV-associated non-Hodgkins
lymphoma [8].
As yet there has been limited work measuring the simultaneous
expression of activation and differentiation markers on HIV-specific
T cells [14–16]. Here, we used polychromatic flow cytometry to
examine the co-expression of CD38, CD27 and CD28 on total T
cells and antigen-specific (HIV, CMV) T cells in a cohort of adults
in early HIV-1 infection (within 6 months of acquisition). This
approach allowed us to examine the relationship between T cell
activation and differentiation, relate these profiles to HIV clinical
markers among recently HIV-1 infected adults, and determine if
effective anti-retroviral therapy can durably alter these profiles. We
observed that HIV-1 Gag-specific CD8+ T cells were predomi-
nantly of an IM phenotype and were significantly more activated
than LM Gag-specific CD8+ T cells. Individuals with the highest
CD8+ T cell activation levels also had the greatest proportion of IM
Gag-specific CD8+ T cells while those with the highest proportion
of more differentiated LM Gag-specific CD8+ T cells had the
highest CD4+ T cell counts. Together these data suggest that the
presence of mature Gag-specific CD8+ T cells with low levels of
activation may be protective during early infection. Our analysis
may serve as a resource to researchers who seek to understand the
relationship of key T cell markers to one another, as part of an effort
to describe an effective T cell response to HIV-1.
Results
Demographic, laboratory and clinical markers at all three study
time-points (pre-therapy baseline visit 1, on anti-retroviral therapy
visit 2, and post-anti-retroviral therapy visit 3) are shown in
Table 1.
Magnitude of T cell responses to HIV-1 Gag and CMV
pp65 over time
The magnitude of IFN-c and IFN-c/IL-2 CD8+ T cell
responses to HIV-1 Gag were lower than the response to CMV
pp65 at visit 1 (prior to therapy), and subsequent study time points
during and after anti-retroviral therapy (Fig. 2). The magnitude of
Gag IFN-c CD8+ T cell responses declined during virologically
suppressive anti-retroviral therapy, while the magnitude of
responses for CMV pp65 did not change.
Table 1. Demographic, Clinical and Laboratory Measures By Study Time-point
Study Entry On Treatment* Post-Treatment
Measurement
N1 3 1 1 1 1
Median (IQR) P=** P=**
CD4+T cell count (cells/mL) 522 (490, 671) 899 (612, 1170) 0.004 715 (579, 1181) 0.04
Viral Load (log10 c/mL) 4.95 (4.1, 5.7) 2.31 (2.31, 2.31) 0.004 4.05 (2.87, 4.89) 0.05
CD8+ T cell Activation (% CD38, HLA-DR) 56.9 (37.5, 75.1) 21.1 (15.7, 29.4) 0.0002 37.5 (30.7, 57.1) 0.08
CD38 MFI, HIV-1 Gag IFN-c+ CD8+ T cells 16825 (5523, 29874) 1614 (1057, 2697) 0.0002 6618 (3053, 7279) 0.03
16825 (5523, 29874)
HIV-1 Gag specific IFN-c+ CD8+ T cells (%) 0.22 (0.14, 1.11) 0.34 (0.26, 0.47) 0.54 0.76 (0.61, 1.88) 0.08
CMV pp65 specific IFN-c+ CD8+ T cells (%) 1.68 (0.19, 2.57) 1.6 (0.24, 3.19) 0.34 2.65 (1.49, 4.40) 0.002
Age (Years) 32 (30, 39)
Estimated Length of Infection (Weeks) 10 (7, 12)
Weeks From Study Entry 28 (18.2, 4.5)
Weeks Spent on Anti-Retroviral Treatment* 49.2 (19.4, 66.3)
Weeks Anti-Retroviral Treatment Stopped 13.4 (4.4, 24.1)
Ethnicity
White 11 (85%)
Hispanic 2 (15%)
Male Gender 13 (100%)
CMV Positive 12 (92%)
*Treatment (anti-retroviral therapy) is defined as at least 2 nucleoside reverse transcriptase inhibitors, and either 1 protease inhibitor (PI), 1 non-nucleoside reverse
transcriptase inhibitor (nnRTI), or a PI and a nnRTI. All patients were treatment naı ¨ve at study entry.
**Difference from Study Entry Values (Sign Rank Test).
doi:10.1371/journal.pone.0004408.t001
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Differentiation of Total T cell subsets. At visit 1, prior to
anti-retroviral therapy, the naı ¨ve and early memory CD8+ T cell
subset (EM:CD27+CD28+) was most frequent (median 43.3%
Interquartile range (IQR) 41.4, 49.7) followed by the intermediate
memory (IM:CD27+CD282, median 31.20% (IQR 23.8, 44.6))
and late memory (LM:CD272CD282) median 16.3% (IQR 10.8,
33.4)) subsets (Fig. 3). Following initiation of anti-retroviral therapy
the total CD8+ T cell population shifted out of the intermediate
memory CD27+CD282 phenotype, with a greater fraction now
falling in the early memory CD27+CD28+ CD8+ T cell
population. Once therapy was halted there was a partial but
incomplete shift towards an expansion of the intermediate memory
pool, but this fraction remained below pre-treatment levels. The
total CD4+ T cell differentiation profile did not shift in response to
treatment.
Differentiation phenotype of HIV-1 Gag- and CMV pp65-
specific T cells. We observed that the maturation profiles of
Figure 1. Expression of Maturation and Activation markers on Total CD4+ and CD8+ T cells. (A): before initiation of ART (i); after
treatment (ii); and post-ART (iii). Activation is also shown on CD27 and CD28 subsets from CD8+ T cells post-ART (iv). Expression of Maturation and
Activation markers on HIV Gag- and CMV pp65-specific T cells (B). CD27 and CD28 expression and CD38 mean fluorescent intensity (MFI) is shown on
IFN-c+ CD8+T cells. (GM=Geometric Mean).
doi:10.1371/journal.pone.0004408.g001
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populations. HIV-1 Gag-specific IFN-c expressing CD8+ T cells
were predominantly CD27+CD282, IM (56.6% (IQR 51.3,
65.3)), while the majority of CMV pp65-specific CD8+ T cells had
a LM CD272CD282 phenotype (58.7% (40.7, 67.2)) (Fig. 3).
HIV-1 Gag-specific CD4+ T cells were almost entirely in the EM
CD27+CD28+ pool, while a greater fraction of pp65-specific
CD4+ T cells were in the LM CD272CD282 pool (Fig. 3). The
maturation profile of HIV-1 Gag-specific and CMV pp65-specific
CD8+ T cell responses did not change after the initiation of anti-
retroviral therapy, or once therapy was halted (Fig. 3). In response
to therapy the proportion of CMV pp65-specific CD4+ T cells in
the CD27+CD282 fraction declined and a co-responding increase
was seen in the CD27+CD28+ fraction, a change which remained
once therapy was halted.
Activation
Activation of EM, IM and LM subsets of Total CD8+ and
CD4+ T cells. Typical of early HIV-1 infection, the proportion
of activated CD8+ T cells was high (median CD38+HLA-DR+
56.9%, Table 1), and was highest among the IM CD27+CD282
pool (median CD38+HLA-DR+ 71.4% (56.6, 85.6), Figure 4).
The proportion of EM CD27+CD28+ (naı ¨ve and early memory)
CD8+ T cells that were activated was variable between subjects
(median CD38_HLA-DR+ 52.2% (28, 71.5) (Fig. 4). The LM
CD27+CD282 subset had the lowest proportion of activated cells
(median CD38+DR+ 35.3% (IQR 28.7, 51.6)) (Fig. 4). The
median proportion of activated total CD4+ T cells was
considerably lower than CD8+ T cells (Fig. 4).
T cell activation and differentiation state of antigen-
specific CD8+ T cell populations. At visit 1, prior to
treatment, Gag-specific CD8+ T cells were significantly more
activated (higher CD38 MFI) than CMV pp65-specific CD8+ T
cells; this was also true for each of the maturation subsets
(EM,IM,LM) (Fig. 4). Of the Gag-specific CD8+ T cell subsets the
EM and IM populations had a similar, though highly variable level
of activation (median EM CD38 MFI, 18340 (IQR 5401, 29205);
median IM CD38 MFI, 18566 (IQR 6950, 31203)) while
activation was lowest on the most mature LM subset (median
CD38 MFI, 9071 (IQR 5613, 12819)) (Fig. 4).
Relationship of T cell activation to maturation profile of
T cell populations. At study visit 1, during early untreated
Figure 2. Magnitude of CD4+ and CD8+ T Cell Responses to HIV-1 Gag and CMV pp65. at each of the three study visits. Proportion of
IFN-c+ and IFN-c+IL-2+ CD8+ (columns 1 and 2) and CD4+ (columns 3 and 4) T cells, responding to stimulation with Gag and pp65 peptide pools.
Results for visit 1, prior to antiretroviral therapy visit 2, during a virologically suppressive anti-retroviral regimen, and visit 3, after patients had halted
an anti-retroviral regimen and viremia had rebounded are shown in upper, middle and lower rows respectively. Black bars indicate differences
between HIV-1 Gag and CMV pp65 responses by response category (Wilcoxon 2 Sample Test). Red dot (1
st column, 2
nd row) notes a significant
change from baseline (visit 1) values (Sign Rank Test). Only the CD8+ T cell IFN-c response to Gag was observed to significantly change (in this case
decline) from visit 1 to either visit 2 or visit 3.
doi:10.1371/journal.pone.0004408.g002
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T cell activation level and maturation profile of total and HIV-1
Gag specific T cell responses (Figure 5). Among untreated persons
at this early infection time-point with high CD8+ T cell activation
levels, we observed a greater fraction of both total and HIV-1 gag
specific CD8+ T cells fall into the intermediate memory
(CD27+CD282) phenotype (figure 5). There was no relationship
between the proportion of CD8+ T cells that were activated and
either the early memory or late memory fractions of total or Gag-
specific CD8+ T cells (data not shown). There was also no
relationship between the proportion of CD8+ T cells that were
activated and the early, intermediate or late memory fractions of
total or Gag-specific CD4+ T cells. For CD4+ T cell responses, at
high CD8+ T cell activation levels we did observe that a smaller
fraction of HIV-1 Gag specific CD4+ T cells fell into the early
memory (CD27+CD28+) pool. There were insufficient cells in the
IM and LM CD4+ Gag specific pools to evaluate their relationship
with CD8+ T cell activation. We did not observe any relationship
between the proportion of activated CD8+ T cells and the size of
CMV-specific early, intermediate or late memory fractions.
Activation, Maturation and Clinical Disease
Markers. The size of any differentiation stage of the HIV-1
Gag IFN-c+ CD8+ T cell response was not associated with viral
load (not shown). A higher fraction of HIV-1 Gag specific IFN-c
expressing CD8+ T cells in the LM pool was found to associate
with higher CD4+ T cell counts (Fig. 6).
Summary of Longitudinal Effects of Anti-Retroviral
Therapy on Observed Phenotypes. Although there was a
sharp decline in the level of activation (CD38 MFI) on HIV-1 Gag
specific CD8+ T cells, there was no significant drop in the
fractional size of the CD8+ T cell HIV-1 Gag specific IM
CD27+CD282 population (Fig. 7), or increase in the fractional
size of HIV-1 Gag specific LM CD8+ T cell pool. Once therapy
was halted, CD38 expression increased on Gag-specific CD8+ T
cells, while there was no net change in the fractional size of IM or
LM sub-populations from pre-treatment (Fig. 7).
Figure 3. Differentiation profile of total and antigen specific T cells over time. In the first column the proportion of total T cells (CD8+ and
CD4+) falling into each T cell maturation category are displayed and defined as early memory (CD27+CD28+) EM, intermediate memory
(CD27+CD282) IM, and late memory (CD272CD282) LM. In columns 2 the maturation profiles for CD8+ T cell IFN-c responses to both HIV-1 Gag
(red) and CMV pp65 (green) are shown. And in column 3 the maturation profiles for CD4+ T cell IFN-c responses to HIV-1 Gag (red) and CMV pp65
(green) are shown. Row 1 displays measurements for visit 1, prior to antiretroviral therapy. Row 2 displays measurements for visit 2, during a
virologically suppressive anti-retroviral regimen, and row 3 displays measurements for visit 3, after patients had halted an anti-retroviral regimen and
viremia had rebounded. Black bars indicate differences between HIV-1 Gag and CMV pp65 responses by response category (Wilcoxon 2 Sample Test).
Red dots note a significant change from baseline (visit 1) values (Sign Rank Test).
doi:10.1371/journal.pone.0004408.g003
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(CD8+ and CD4+) expressing CD38 and HLA-DR activation markers by T cell maturation category are displayed and defined as early memory
(CD27+CD28+) EM, intermediate memory (CD27+CD282) IM, and late memory (CD272CD282) LM. In columns 2 the CD38 MFI level is shown by
maturation stage for CD8+ T cell IFN-c responses to both HIV-1 Gag (red) and CMV pp65 (green). And in column 3 the CD38 MFI is shown for each
maturation stage of CD4+ T cell IFN-c responses to HIV-1 Gag (red) and CMV pp65 (green). Row 1 displays measurements for visit 1, prior to
antiretroviral therapy. Row 2 displays measurements for visit 2, during a virologically suppressive anti-retroviral regimen, and row 3 displays
measurements for visit 3, after patients had halted an anti-retroviral regimen and viremia had rebounded. Black bars indicate differences between
activation levels by response categories (Wilcoxon 2 Sample Test). Red dots notes a significant change from baseline (visit 1) values (Sign Rank Test).
doi:10.1371/journal.pone.0004408.g004
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In an effort to understand the relationship of two key features of
the early T cell response to HIV-1 we examined the simultaneous
expression of both activation and differentiation markers on total
and antigen-specific T cells from treatment naı ¨ve adults in early
HIV-1 infection before, during and after anti-retroviral therapy.
Our data suggests that there may be a link between the activation
and maturation stage of CD8+ T cells. The skewed, less
differentiated maturation profile of HIV-1-specific T cells was
more pronounced at higher CD8+ T cell activation levels. We also
found that increased numbers of fully differentiated HIV-1-specific
CD8+ T cells associated with higher CD4+ T cell counts
suggesting that the presence of mature Gag-specific CD8+ T cells
may be protective. However the HIV-1 Gag-specific T cell
differentiation profile was not readily altered by suppression of T
cell activation by anti-retroviral treatment.
We compared CMV- and HIV-1-specific responses in early
infection. Previous studies of differences between CMV- and HIV-
specific-responses have suggested that the failure of HIV-specific
cells to reach a more differentiated phenotype may explain their
inability to fully control HIV replication [12,17]. The magnitude
of CD8+ IFN-c+ and IFN-c+IL-2+ T cell responses to CMV pp65
were considerably higher than those for HIV-1 Gag. CMV pp65-
specific CD8+ T cells had a greater proportion of the more mature
LM (CD272CD282) cells compared with Gag-specific CD8+ T
cells. The level of activation on all subsets of pp65-specific cells was
much lower than on Gag-specific cells. These data suggest that a
low activation state, a high magnitude of CMV specific IFN-c and
IL-2 responses, and a high proportion of mature CMV specific
CD8+ T effector cells may be important features in the control of
CMV.
It has been suggested that distinct T cell maturation profiles,
associated with responses to different viruses, are established for
the purpose of generating memory or maintaining latency [9]. A
recent report suggested that protective Class I B*27 HIV-1 KK10-
specific CD8+ T cells have a intermediate differentiation
phenotype (CD27+CD282CD45RA-CCR7-) that was indistin-
guishable from CD8+ T cells specific for other less-protective
HIV-1 epitopes [18]. This may indicate that an intermediate
differentiation phenotype can be associated with protection. That
said, in agreement with our finding that a more differentiated
HIV-1 specific CD8+ T cell response is associated with higher
CD4 counts two recent clinical studies have suggested that more
differentiated CD8+ T cell responses are associated with lower
HIV-1 viral load set point, or long-term non-progressor status in
HIV-1 disease [10,11]. Lower CD8+ T cell activation may mark
or induce a state of less differentiated total and CD4+ T cell
responses. This in turn may amount to a lower fraction of IM
CD4+ T cells expressing CCR5 and lower cell turn-over,
rendering the CD4+ T cell population less susceptible to infection.
The reverse state - of higher CD8+ T cell activation - may
Figure 5. Relationship of Total CD8+ T Cell Activation to T Cell Maturation Profiles. Relationship between total CD8+ T cell activation
levels at visit 1 (pre-treatment) on the x-axis and the maturation profile of CD8+ and CD4+ T cell populations, total or antigen specific. In the first
panel total CD8+ T cell activation is higher when a greater fraction of total CD8+ T cells fall in the intermediate memory (CD27+CD282) phenotype. In
the second panel total CD8+ T cell activation levels are higher when a greater fraction of HIV-1 Gag specific CD8+ T cells fall in the intermediate
memory (CD27+CD282) phenotype. In the third panel total CD8+ T cell activation levels are lowest when a lower fraction of HIV-1 Specific CD4+ T
cells fall into the early memory (CD27+CD28+) phenotype.
doi:10.1371/journal.pone.0004408.g005
Figure 6. A More Differentiated Gag Specific CD8+ T Cell Response is Protective in Early HIV-1 Infection. Spearman Correlation results
shown. Correlation performed on data from pre-treatment, Visit 1. Patients with higher CD4+ T cell counts during early infection and prior to anti-
retroviral therapy tended to have higher HIV-1 Gag specific IFN-c late memory (CD272CD282) CD8+ T cells
doi:10.1371/journal.pone.0004408.g006
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expansion of EM CD4+ T cells into an IM pool. This stimulation,
in the absence of cognate antigen could lead to apoptosis, or direct
viral infection and cell death.
We found that patients with the highest numbers of EM Gag-
Specific CD4+ T cells had the lowest levels of T cell activation,
suggesting that – in contrast to our findings on CD8+ T cell
responses – that a less differentiated CD4+ T cell response may be
associated with better clinical status. Our data is consistent with a
report suggesting a less differentiated CD4+ T cell response marks
long-term non-progression in HIV disease, a state of low CD8+ T
cell activation [19].
Repeated stimulation of Gag-specific T cells, by persistent HIV-
1 replication, may induce high levels of activation and block
maturation into a mature effector phenotype. Based on our model
linking activation to maturation impairment, we reasoned that in
the absence of repeated antigen stimulation the proportion of Gag-
specific T cells with a low activation, LM phenotype may increase.
We therefore examined maturation and activation following anti-
retroviral therapy and reduction of circulating virus to undetect-
able levels. While a significant decline in activation levels on all
CD8+ T cell subsets was apparent, reduced antigen load had
different effects on total, CMV- and HIV-1-specific T cell
differentiation profiles. Following therapy, the CMV-specific
CD4+ IM T cell pool did expand as the LM pool shrunk. This
suggests that HIV-1 viremia, or generalized immune activation
may influence the differentiation profile of CMV specific CD4+ T
cell responses. Among total CD8+ T cells there was a significant
reduction in the IM and a corresponding increase in the LM
fraction. As activation declines the total IM CD8+ T cell fraction
may mature, or die by apoptosis, shifting the population to an LM
profile. In contrast, despite a significant reduction of activation
levels on Gag-specific CD8+ T cells, there was no corresponding
shift in the maturation profile of Gag specific CD8+ T cells. Taken
Figure 7. T cell activation declines during anti-retroviral therapy but maturation profile of Gag specific CD8+ T cells does not
change HIV-1 RNA levels, total CD8+ T cell activation levels, HIV-1 specific CD8+ T cell activation levels and the proportion of HIV-1 Gag specific IM
and LM CD8+ T cells at visit 1 (Pre-ART), visit 2 (On ART) and visit 3 (Post-ART). P-values for changes in viral load, Total and HIV-1 specific CD8+ T cell
activation are shown in Table 1. HIV-1 RNA, total CD8+ T cell activation levels and HIV-1 gag specific CD8+ T cell activation levels all declined after
initiation of ART. Black bars display p-values for a test of change in HIV-1 Gag specific CD8+ T cell IM and LM fractions from visit 1 to visit 2, and visit 3.
Neither the Gag specific IFN-c+ CD8+ IM or LM pool changed significantly from pre-therapy levels after therapy was initiated (On ART), or later halted
(Post-ART).
doi:10.1371/journal.pone.0004408.g007
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not prevent the maturation of Gag-specific cells, although these
effects may be apparent on T cells of other specificities. The Gag-
specific T cells that we measured may have already become
replicatively senescent due to repeated stimulation [16].
The mechanism by which maturation and activation are
associated prior to treatment is not clear from our results. The
relative paucity of LM HIV-specific CD8+ T cells may be due to
increased susceptibility of these to apoptosis, even after ART
suppression of activation. That said, the failure of CD8+ T cells to
mature may result from manipulation of signaling pathways in
responding HIV-1 specific CD8+ T cells by a viral product, such
as secreted Nef, which has been shown to upregulate PD-1 [20].
Indeed PD-1, which is associated with anergy of antigen-specific
cells, is upregulated on HIV- but not CMV-specific CD8+ T cells
[21] and could prevent maturation to an effector cell type. It has
also been suggested that lack of IL-2 production by HIV-1-specific
CD8+ T cells may explain their inability to down-regulate CD27
[17]. Recently it was shown that CD27 down-regulation can be
blocked by lack of expression of its ligand, CD70 [22] which
requires both antigen and cytokines, including IL-2 for expression.
In our study the proportion of Gag-specific CD8+ IL-2 expressing
cells was very low (Fig. 3) supporting the idea that the absence of
IL-2 producing HIV-1-specific T cells may be unable to prevent
CD27 down-regulation [22].
We observed that HIV-specific T cells are predominantly
immature and highly activated at early stages of infection.
Although activation is reduced by anti-retroviral therapy imma-
ture Gag-specific cells continue to predominate. In a previous
report we demonstrated that initiation of anti-retroviral therapy
within the first month of HIV-1 infection associated with improved
viral control and clinical outcomes once therapy was halted,
compared to those who start anti-retroviral therapy one month or
later into infection [23]. In our current study, persons initiated
therapy no earlier than 2 months after acquiring HIV-1, by which
time a sub-optimal HIV-1 specific T cell differentiation profile was
established. It would be of interest to examine the activation and
maturation profile of cells from individuals treated within one
month of infection. Earlier intervention with anti-retroviral
therapy may lower T cell activation during very early infection,
alter the T cell differentiation phenotype of responding CD8+ T
cells, or both, in a manner which confers enhanced T cell
mediated control of HIV-1.
Materials and Methods
Overview
Thirteen treatment naı ¨ve adults in early HIV infection were
studied for T cell responses and phenotypes at 1) study entry
(within 2–4 months of acquiring infection), 2) after having reached
complete virologic suppression on a first anti-retroviral regimen
(defined as 2 nucleoside reverse transcriptase inhibitors, and at
least 1 protease inhibitor and/or 1 non-nucleoside reverse
transcriptase inhibitor) and 3) several months after having halted
anti-retroviral therapy.
San Francisco Recent HIV-1 Infection Cohort. All
specimens were drawn from persons enrolled in the Options
study of early HIV-1 infection conducted in a university based
research clinic. Among those enrolled in OPTIONS,
approximately 90% are within 6 months of acquiring HIV-1
infection [24]. Patients were determined to be in early HIV-1
infection via an algorithm employed by the Acute Infection and
Early Disease Research Program. This algorithm employs
information on serial HIV-1 antibody testing, de-tuned EIA
scores [25,26], RNA PCR detection, HIV-1 protein western blot
banding patterns and self reported risk behaviors to estimate time
since infection. Only persons estimated to be within 1 year of
infection are enrolled in the parent cohort (OPTIONS), and most
patients are within 3 to 6 months post-infection at the time they
enroll. Information on estimated length of infection for study
participants may be found in Table 1. All participants gave
written, informed consent using protocols approved by the
Committee on Human Research, University of California, San
Francisco.
Cell Specimens. PBMC were isolated, cyropreserved and
stored by the UCSF/ARI AIDS Specimen Bank, then transported
to the Core Immunology Laboratory for analysis. Cryopreserved
PBMCS were rapidly thawed in to warm RPMI 1640 with 10%
fetal bovine serum (UCSF Cell Culture Facility) and counted using
the Viacount assay on a Guava Personal Cell Analysis system
(Guava Technologies). For Cytokine Flow Cytometry (CFC) assays
PBMC were re-suspended at 1610
6–2610
6 cells/mL in the same
medium, and rested overnight in slanted 15-mL conical tubes with
loosened caps, in a CO2 incubator at 37uC. For phenotyping
assays cells were washed in FACS buffer (PBS with 1% Bovine
Serum Albumin, Sigma Aldrich) for staining the same day.
T cell activation and maturation. Thawed PBMCS were
surfaced stained with the following combination of fluorescently
labeled antibodies: CD3 Pacific Blue, CD4-AmCyan, CD8-Alexa
700, CD38-PE-CY7, CD27-APC, CD28-APC-CY7, and HLADR
FITC (all BD Biosciences) in the presence of 5 mg/ml ethidium
monoazide bromide (EMA, Invitrogen). After a 50 minute
incubation in the dark at 4uC cells were exposed to a 40-W
fluorescent light for 10 min at room temperature to cross-link the
EMA. FMO (Fluorescent minus-one) controls were run with each
experiment to ensure that breakdown of tandem conjugates (e.g.
APC-CY7 to APC) was not occurring and to assist with setting
gates. Following staining, PBMCs were washed in FACS buffer,
fixed in 0.5% formaldehyde (Polyscience), stored at 4uC until
analysis.
Antigen Specific CD4+ and CD8+T cells. Thawed and
rested PBMC were stimulated with overlapping peptide pools (all
15mers overlapping by 11 aa) in the presence of 10 mg/ml
Brefeldin A (Sigma Aldrich) for 18 hours at 37uC. Peptide pools
were HIV-1 SF2 GAG (4.8 mg/mL, SynPep) and CMV pp65
(4.25 mg/mL, SynPep). Unstimulated cells were run in parallel as
a negative control for each subject. Following stimulation PBMCs
were treated with 2 mmol/L EDTA, washed in PBS, then stained
with anti-CD4, CD8, CD38, CD27, and CD28 in the presence of
EMA, as described above. Cells were then washed in FACS buffer,
fixed and permeabilized by a 10 minute incubation in FACS lyse,
and a 10 minute incubation in FACS Perm (both from BD
Biosciences) before staining with fluorescently conjugated
antibodies: IFN-c-FITC, IL-2-PE and CD3-Pacific Blue (all BD
Bioscience). Cells were washed, re-suspended in FACS buffer,
stored at 4uC until analysis.
Flow Cytometry. All samples were run on a customized BD
LSR II Flow cytometer within 18 hours of staining. Rainbow
beads (Spherotec) were used to standardize instrument settings
between runs. Between 900,000 and 1 million lymphocytes were
collected for each sample. Data was compensated and analyzed by
using Flowjo Software (Treestar Inc). The gating strategies used to
define CD4+ and CD8+ T cell maturation and activation
populations, to define antigen-specific T cells, and to subset
these cells for activation and maturation markers are shown in
figure 1. We defined a T cell response as the percent of cells
expressing cytokine in response to HIV Gag or CMV pp65 after
subtraction of background signal. The proportion of CD8+ T cells
CD8+ Activation and Maturation
PLoS ONE | www.plosone.org 10 February 2009 | Volume 4 | Issue 2 | e4408responding to antigen stimulation varied from 0 to 7.5% (median
IFNc+ response 0.46% to Gag and 1.6% to pp65) and in some
cases insufficient cytokine positive events were obtained to
determine the level of activation or maturation markers. CD4+
T cells responses were low for some subjects (median IFNc+
response 0.072% to Gag and 0.15% to pp65). We restricted the
analysis of maturation markers to responses where greater than
100 IFNc+ events were collected. As a result we do not present
subset analyses of the IFN-g\IL-2 responding populations, nor do
we present the expression of CD38 MFI on antigen-specific CD4+
T cell responses as the IM and LM populations were scarce. The
activation state of antigen specific cells was measured by
examining the median fluorescence intensity (MFI) of CD38 on
each differentiation stage. In this analysis we measured CD38 MFI
expression on the IFN-c expressing CD4+ or CD8+ T cell
population. We assigned the CD8+ T cell differentiation stages
according to the scheme proposed by Appay as Early Memory
(EM) for CD27+CD28+, Intermediate Memory (IM) for
CD27+CD28- and Late Memory (LM) for CD272CD282
CD8+ T cells [12,27]. For CD4+ T cells the categories were the
same, except that the Intermediate Memory (IM) CD4+ T cells
are defined as CD272CD28+.
Statistical Analysis. All statistical analyses were performed
in the SAS System Version 9.1 for Windows XP. Non-parametric
statistical tests were employed in all cases. Spearman rank
correlations were generated for all correlation tests. Signed Rank
tests were used to test significance of change in values between
study time-points. The Wilcoxon Two Sample test was used to
compare different values at a given study time-points.
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